¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"myeloid series"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® upper GI series ÇÑ±Û »óºÎÀ§Àå°üÁ¶¿µ¼ú
¼³¸í   
  X-¼± »çÁø¿¡¼­ Àß ³ªÅ¸³ª´Â Á¶¿µÁ¦(¹æ»ç¼±ÃÔ¿µ»ó¿¡¼­ ÇϾé°Ô ³ªÅ¸³ª ÁÖÀ§Á¶Á÷°ú °¨º°ÀÌ ¿ëÀÌÇÏ´Ù)¸¦ ¼·ÃëÇÑ ÈÄ ½Äµµ, À§, »ùâÀÚ, ÀÛÀºÃ¢ÀÚ»óºÎ±îÁö X-¼± ÃÔ¿µÇϹǷνá, ±×°÷ ¼ÒÈ­°ü³»ÀÇ ÀÌ»óº´ÅÍ¿©ºÎ¸¦ °Ë»çÇϴ °Í. Á¶¿µÁ¦´Â ÁַΠ¹Ù·ýÀ» »ç¿ëÇϸ破õ ¼±¸íÇÑ ¿µ»óÀ» ¾ò±âÀ§ÇØ ¹ßÆ÷Á¦¸¦ ÇÔ²² ¼·ÃëÇÏ¿© ¹Ù·ý°ú °ø±âÀÇ ÀÌÁßÁ¶¿µÃÔ¿µÀ» Çϱ⵵ ÇÑ´Ù. ½Äµµ¾Ï, À§¾Ï ¹× ¼ÒÈ­¼º±Ë¾ç°ú ±×¹Û¿¡ ´Ù¾çÇÑ º´º¯ÀÇ Áø´Ü¿¡ È¿°úÀûÀ¸·Î »ç¿ëµÈ´Ù.
¿µ¹® small bowel series ÇÑ±Û ÀÛÀºÃ¢ÀÚ Á¶¿µ¼ú, ¼ÒÀå Á¶¿µ¼ú
¼³¸í   
  ¹æ»ç¼± Á¶¿µÁ¦(¹æ»ç¼±°Ë»ç¿¡¼­ ´Ù¸¥ ºÎÀ§¿Í ´ëÁ¶µÇ´Â ¾ÆÁÖ Èò»öÀ» ¶ì´Â ¹°Áú)ÀΠ¹Ù·ýÀ» ¼·ÃëÇÑ µÚ, ÃÔ¿µÇϴ ÀÛÀºÃ¢ÀÚÀÇ ±âº»ÀûÀΠ¹æ»ç¼± °Ë»ç·Î¼­, ¹æ¹ýÀº 200~300mLÀÇ ¹Ù·ýÀ» ¸ÔÀºµÚ ¹Ù·ýÀÌ ÀÛÀº Ã¢ÀÚ¸¦ Åë°úÇϴ µ¿¾È Á¤±ÔÀû °£°ÝÀ¸·Î ¹æ»ç¼± »çÁøÀ» ÂïÀ½. ÀϹÝÀûÀ¸·Î 2~3½Ã°£ÀÌ °É¸².
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸí°ñ¼öÈ­»ý
  • myeloid
    °ñ¼ö¸ð¾ç-, °ñ¼ö¼º
  • myeloid cell
    °ñ¼ö¼¼Æ÷
  • myeloid metaplasia
    °ñ¼öÈ­»ý
  • aromatic series
    ¹æÇâÁ·°è¿­
  • aliphatic series
    Áö¹æÁ·°è¿­
  • discrete series
    ºÒ¿¬¼Ó¼ö¿­
  • exponential series
    Áö¼ö±Þ¼ö
  • granulocytic series
    °ú¸³±¸°è¿­
  • homologous series
    µ¿Á·°è¿­
  • ionization series
    ÀÌ¿ÂÈ­°è¿­
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • series
    1. °è¿­ 2. ±Þ¼ö 3. Á÷·Ä
  • series elastic component
    Á÷¿­Åº·Â¼ººÐ
  • series limit
    °è¿­±ØÇÑ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • series
    °è¿­, ±Þ¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸí°ñ¼öÈ­»ý
  • myeloid cell
    (¢¡marrow cell) °ñ¼ö¼¼Æ÷
  • myeloid
    °ñ¼ö¸ð¾ç-
  • myeloid metaplasia
    °ñ¼öÈ­»ý
  • aliphatic series
    Áö¹æ°è¿­
  • aromatic series
    ¹æÇâÁ·°è¿­
  • commutator series
    ±³È¯ÀÚ¿­
  • series elastic component
    Á÷¿­Åº·Â¼ººÐ
  • discrete series
    ºÒ¿¬¼Ó¼ö¿­
  • exponential series
    Áö¼ö±Þ¼ö
  • granulocytic series
    °ú¸³±¸°è¿­
  • homologous series
    µ¿Á·°è¿­
  • hypergeometric series
    ÃʱâÇϱ޼ö
  • ionization series
    ÀÌ¿ÂÈ­°è¿­
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸíÀÇ °ñ¼öÈ­»ýÁõ.
  • agnogenic(idiopathic) myeloid metaplasia
    ¿øÀκҸí(Ư¹ß¼º) °ñ¼öÈ­»ýÁõ(ê«ì×ÝÕÙ¥ ÍéâÐûùßæñø)
  • immature myeloid element
    ¹Ì¼÷°ñ¼ö¼º Ç÷__¡­ÍéâÐàõúìϹ).
  • immature myeloid element
    ¹Ì¼÷°ñ¼ö¼º Ç÷±¸(?Ë­ËàËÛÌ´Ë´).
  • Hofmeister s series =lyotropic s.
    È£ÇÁ¸¶À̽ºÅͰ迭(¡­Í§æê).
  • aliphatic series
    Áö¹æ°è¿­.
  • arithmetic series
    µîÂ÷±Þ¼ö.
  • aromatic series
    ¹æÇâÁ·¿­(¡­ðéæê).
  • gallbladder series
    ´ã³¶Á¶¿µ°Ë»ç.
  • gallbladder series
    ´ã³²Á¶¿µ°Ë»ç
  • homologous series
    µ¿Á·°è¿­(¡­Í§æê).
  • hypergeometric series
    ÃʱâÇϱ޼ö(̧˻̰˻Ëà).
  • principal series
    ÁÖ°è¿­(̡˭Ëç).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gastrointestinal series =GI series
    ¹æ»ç À§Àå°üÁ¶¿µ¼ú.
  • agnogenic myeloid metaplasia
    ¿øÀκҸíÀÇ °ñ¼öÈ­»ýÁõ.
  • agnogenic(idiopathic) myeloid metaplasia
    ¿øÀκҸí(Ư¹ß¼º) °ñ¼öÈ­»ýÁõ(ê«ì×ÝÕÙ¥ ÍéâÐûùßæñø)
  • aleukemic myelosis=myelofibrosis with myeloid metaplasia
    ¹«¹éÇ÷¼º °ñ¼öÁõ
  • extramedullary myeloid cell tumor
    °ñ¼ö¿Ü°ñ¼ö¼¼Æ÷Á¾
  • immature myeloid element
    ¹Ì¼÷°ñ¼ö¼º Ç÷±¸(?Ë­ËàËÛÌ´Ë´).
  • immature myeloid element
    ¹Ì¼÷°ñ¼ö¼º Ç÷__¡­ÍéâÐàõúìϹ).
  • leukemia,myeloid, chronic
    ¸¸¼º °ñ¼ö¼º(Ø·àõ ÍéâÐàõ)
  • mature myeloid element
    ¼º¼÷°ñ¼ö¼º Ç÷±¸(?Ë­ËàËÛÌ´Ë´).
  • mature myeloid element
    ¼º¼÷°ñ¼ö¼º Ç÷±¸(¡­ÍéâÐàõúìϹ).
  • myelofibrosis with myeloid metaplasia
    °ñ¼ö¾çÈ­»ý(åÆûùßæ)°ñ¼ö¼¶À¯Áõ
  • myeloid
    °ñ¼ö¾ç(Ë­ËàËâ)ÀÇ.
  • myeloid antigen
    °ñ¼ö¾ç(ÍéâÐåÆ) Ç׿ø
  • myeloid cell
    °ñ¼ö¼¼Æ÷(¡­á¬øà).
  • myeloid cell
    °ñ¼ö¼¼Æ÷(?ËṴ̂).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Myeloid tissue
    °ñ¼öÁ¶Á÷
    [¿¾ ¿ë¾î] °ñ¼ö¾çÁ¶Á÷
  • Myeloid tissue
    °ñ¼öÁ¶Á÷ [»À¼ÓÁúÁ¶Á÷]
    [¿¾ ¿ë¾î] °ñ¼ö¾çÁ¶Á÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • chaotropic series
    ¹«Áú¼­(Ùíòñßí) ¾¾¸®½º
  • decay series
    "ºØ±« °è¿­(ÝÚÎÕ֪ͧ), (µ¿) radioactive series"
  • eluotropic series
    ¿ë¸® ¼­¿­ (éÁ×îßíÖª)
  • globo-series glycosphingolipids
    ±Û·Îº¸°è¿­(֪ͧ) ´ç(ÓØ)½ºÇΰíÁöÁú(ò·òõ)
  • Hofmeister series
    È£ÇÁ¸¶À̽ºÅÍ °è¿­(֪ͧ)
  • homologous series
    µ¿Á· °è¿­(ÔÒðé֪ͧ)
  • lacto-series glycosphingolipid
    ¶ôÅä°è¿­(֪ͧ) ±Û¶óÀÌÄÚ½ºÇΰíÁöÁú(ò·òõ)
  • lyotropic series
    À̾װ迭(ìÆäû֪ͧ)
  • radioactive series
    ¹æ»ç¼º °è¿­(Û¯ÞÒàõ֪ͧ)
  • Trappe's eluotropic series
    Æ®¶óÆä ¿ë¸®¼­¿­(éÁ×îßíÖª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gallbladder series
    ´ã³¶Á¶¿µ°Ë»ç
  • gastrointestinal series
    À§Àå°üÁ¶¿µ¼ú
  • small bowel series
    ¼ÒÀåÁ¶¿µ¼ú
  • upper gastrointestinal series
    »óºÎÀ§Àå°üÁ¶¿µ¼ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MMM see 3-M [syndrome]; microsome-mediated mutagenesis; myelofibrosis with myeloid metaplasia; myeloscle...
UGIS Upper Gastro-Intestinal Series
FMS fat-mobilizing substance; Fellow of the Medical Society; fibromyalgia syndrome; full mouth series
GBS gallbladder series; gastric bypass surgery; group B Streptococcus; general biopsychosocial screening...
GIS gas in stomach; gastrointestinal series; geographic information system; guaranteed income supplement...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SEC Series elastic component
AML Acute Myeloid Leukaemia
AMM Agnogenic myeloid metaplasia
CML Chronic Myeloid Leukaemia
HL-60 Human myeloid leukemia cells
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • agnogenic idiopathic myeloid metaplasia
    ¿øÀÎ ºÒ¸í Ư¹ß¼º °ñ¼ö È­»ýÁõ
  • immature myeloid precussor
    ¹Ì¼º¼÷ °ñ¼ö ¼¼Æ÷
  • myeloid
    °ñ¼ö¼º, °ñ¼öÁõ, °ñ¼ö¾çÀÇ
  • myeloid leukoses
    °ñ¼ö¼º ¹éÇ÷Áõ
  • aromatic series
    ¹æÇâÁ· ¿­
  • Balmer's series
    ¹ß¸Ó °è¿­
  • case-series evaluation
    »ç·Ê Æò°¡
  • electrochemical series
    Àü±â È­ÇÐ ¼­¿­
  • homologous series
    µ¿Á· °è¿­
  • series Á·, ¾Æ°­ÀÇ ÇÏÀ§ÀÌ°í ¸ñÀÇ »óÀ§ÀÎ ºÐ·ùÇÐÀû ¹üÁÖ.

    seriflux

    ¼ö¾ç ¹è¼³¾×, Àå¾× ¹æÃâ, ¿¯Àº ¼ö¾ç¾× ¹æÃâ
  • small bowel series
    ¼ÒÀå Á¶¿µ¼ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
myeloid series The granulocytic and the erythrocytic series.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
agnogenic myeloid metaplasia A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets.
Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably.
Origin: Gr. Plassein = to form
(27 Sep 1997)
chronic myeloid leukaemia <haematology> A leukaemia which is initially slowly-progressing. There are approximately 650 new cases each year in the UK. It is characterised by the presence of large numbers of abnormal mature granulocytes, circulating in the blood.
Synonym: chronic granulocytic leukaemia.
Acronym: CML
Origin: Gr. Haima = blood
(12 Jan 1998)
myeloid Collective term for the nonlymphocyte groups of white blood cells. It includes cells from the granulocyte, monocyte and platelet lineages.
(13 Nov 1997)
myeloid cell <haematology, pathology> One of the two classes of marrow derived blood cells, includes megakaryocytes, erythrocyte precursors, mononuclear phagocytes and all the polymorphonuclear granulocytes. That all these are ultimately derived from one stem cell lineage is shown by the occurrence of the Philadelphia chromosome in these, but not lymphoid, cells. most authors tend, however, to restrict the term myeloid to mononuclear phagocytes and granulocytes and commonly distinguish a separate erythroid lineage.
(12 May 1997)
myeloid metaplasia A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets.
Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably.
Origin: Gr. Plassein = to form
(27 Sep 1997)
myeloid sarcoma <tumour> A malignant tumour of immature myeloid cells, frequently subperiosteal, associated with or preceding granulocytic leukaemia.
See: chloroma.
Synonym: myeloid sarcoma.
(05 Mar 2000)
myeloid tissue Bone marrow consisting of the developmental and adult stages of erythrocytes, granulocytes, and megakaryocytes in a stroma of reticular cells and fibres, with sinusoidal vascular channels.
(05 Mar 2000)
primary myeloid metaplasia Myeloid metaplasia occurring as the primary condition, often in association with myelofibrosis.
Synonym: agnogenic myeloid metaplasia.
(05 Mar 2000)
secondary myeloid metaplasia Myeloid metaplasia occurring in individuals with another disease.
Synonym: symptomatic myeloid metaplasia.
(05 Mar 2000)
symptomatic myeloid metaplasia Myeloid metaplasia occurring in individuals with another disease.
Synonym: symptomatic myeloid metaplasia.
(05 Mar 2000)
leukaemia, myeloid Form of leukaemia characterised by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites.
(12 Dec 1998)
aromatic series All the compounds derived from benzene, or similar cyclic compounds that obey Huckel's rule, distinguished from those compounds that are acyclic or that contain rings that lack the conjugated double bond structure characteristic of benzene.
(05 Mar 2000)
granulocytic series <haematology> The cells in the several stages of development in the bone marrow leading to the mature granulocyte of the circulation, e.g., myeloblasts, different stages of the myelocyte, granulocytes.
(05 Mar 2000)
Hofmeister series <chemistry> The series of cations Magnesium, Calcium, Sr2+, Ba2+, Li+, Na+, K+, Rb+, Cs+, and of anions citrate3-, tartrate2-, SO42-, acetate-, NO3-, CIO3-, I-, CNS- (among others).
Each series is arranged in order of decreasing ability to: 1) precipitate the dispersed substance of lyophilic soltions; 2) "salt out" organic substances (e.g., aniline, ethyl acetate) from aqueous solutions; or 3) inhibit the swelling of gels.
These effects, among other related ones, are ascribable to the abstraction and binding of water by these ions (i.e., hydration), which also decreases in the orders given, so that (in the monovalent cation series) Li+, with the smallest crystal radius, has the largest hydrated radius, and vice versa for Cs+.
Synonym: lyotropic series.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • a series fo
    ÀÏ·ÃÀÇ
  • series
    ¿¬¼ÓµÈ °Í
  • actinide series
    ¾ÇƼ´Ïµå °è¿­;¹æ»ç¼±¿ø¼Ò
  • arithmetic series
    µîÂ÷±Þ¼ö
  • geometric series
    ±âÇÏ(µîºñ)±Þ¼ö
  • harmonic series
    Á¶È­ ±Þ¼ö
  • methane series
    ¸Þź ¿­
  • paraffin series
    ÆÄ¶óÇÉÁ·;¸Þź°è
  • power series
    ¸è±Þ¼ö
  • radioactive series
    ¹æ»ç¼º °è¿­;±«º¯ °è¿­
  • series
    ÀÏ·Ã;¿¬¼Ó;½Ã¸®Áî;¼ö¿­;±Þ¼ö;¿­;Åë;Á÷·Ä;(12À½ À½¾ÇÀÇ)À½·Ä;arithmetical ~ µîÂ÷ ±Þ¼ö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á